Prosecution Insights
Prosecution Insights
7 pending office actions • 6 clients • 7 examiners • 7 art units • 0 of 7 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (14%) |
| §112 only | 2 (29%) |
| Double-patenting + other | 3 (43%) |
| No statute on record | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 43.5% | +57.7% |
| BERRY, LAYLA D | 1 | 65.9% | +8.9% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 59.4% | +26.5% |
| BUNNER, BRIDGET E | 1 | 64.4% | +20.1% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| PECKHAM, RICHARD GRANT | 1 | 67.2% | +37.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18045525 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | OUSPENSKI, ILIA I | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18490804 | MULTISPECIFIC NKp46 BINDING PROTEINS | HUYNH, PHUONG N | 44d overdue |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | BUNNER, BRIDGET E | 28d |
| 18691908 | SOLID FORM OF RHO-ASSOCIATED PROTEIN KINASE INHIBITOR OR SOLVATE THEREOF, PREPARATION METHOD AND USE THEREOF | MOU, LIYUAN | — |
| 18472411 | MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS | ALSOMAIRY, SARAH ABDOALATIF | — |
| 18045525 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | OUSPENSKI, ILIA I | — |
| 17607438 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | PECKHAM, RICHARD GRANT | — |
| Client (Assignee) | Pending OAs |
|---|---|
| BEIJING TIDE PHARMACEUTICAL CO., LTD. | 2 |
| Pharmacosmos Holding A/S | 1 |
| Innate Pharma | 1 |
| Precision Biologics, Inc. | 1 |
| MACROGENICS, INC. | 1 |
| Johnson & Johnson | 1 |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1623 | 1 |
| 1641 | 1 |
| 1646 | 1 |
| 1647 | 1 |
| 1644 | 1 |
| 1627 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18691908 | SOLID FORM OF RHO-ASSOCIATED PROTEIN KINASE INHIBITOR OR SOLVATE THEREOF, PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. | MOU, LIYUAN | 1628 | §103§112DP | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18294572 | IRON COMPLEX COMPOUNDS FOR SUBCUTANEOUS USE IN THERAPY OF IRON DEFICIENCY IN COMPANION ANIMALS | Pharmacosmos Holding A/S | BERRY, LAYLA D | 1623 | §102§103§112DP | Non-Final OA | 83d | Pending | Feb 02, 2024 |
| 18490804 | MULTISPECIFIC NKp46 BINDING PROTEINS | Innate Pharma | HUYNH, PHUONG N | 1641 | §112Other | Non-Final OA | 44d overdue | Pending | Oct 20, 2023 |
| 18472411 | MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS | Precision Biologics, Inc. | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §102§112DP | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | Macrogenics, Inc. | BUNNER, BRIDGET E | 1647 | §112Other | Non-Final OA | 28d | Pending | Mar 06, 2023 |
| 18045525 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Janssen Pharmaceuticals, Inc. | OUSPENSKI, ILIA I | 1644 | §101Other | Non-Final OA | — | Pending | Oct 11, 2022 |
| 17607438 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | BEIJING TIDE PHARMACEUTICAL CO., LTD. | PECKHAM, RICHARD GRANT | 1627 | — | Final Rejection | — | Pending | Oct 29, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial